Press Release FeedGet the RSS feed
Menu

Business Wire

Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026

Johnson & Johnson

  • Company to showcase MONARCH™ robotics platform and Polyphonic™ digital ecosystem

  • New ecosystem collaboration announced at the event will support the future of surgical intelligence

ABU DHABI, United Arab Emirates, October 20, 2026--Johnson & Johnson will showcase digital surgery technologies and its strategic collaboration with the Department of Health – Abu Dhabi (DOH), to advance surgical intelligence at the Abu Dhabi Future Health Summit 2026, joining leaders from healthcare, government, technology, research and investment to accelerate transformative health innovation. Aligned with this year's Summit theme, "To Sense Is to Predict", the collaboration reflects a shared ambition to translate data and insights into informed clinical decisions, responsible innovation and better patient care.

At the Summit, Johnson & Johnson will highlight innovations across its surgery portfolio and convene discussions on surgical intelligence. Attendees will experience innovations including the MONARCH™ platform and the Polyphonic™ digital ecosystem and explore the potential of global surgical intelligence to support surgeons, inform workflows and advance patient care.

"Healthcare is entering an era where data, AI and connected technologies have the potential to help improve patient outcomes by transforming data into insights that can augment surgeons' judgment and inform streamlined workflows," said Shan Jegatheeswaran, President, Polyphonic, MedTech, Johnson & Johnson. "Abu Dhabi has demonstrated a clear ambition to shape the future of healthcare, and we are honored to participate in this important forum alongside our partners and physicians as we advance the next chapter of surgical innovation."

Key Johnson & Johnson Activities at Future of Health

Mainstage Discussion | Johnson & Johnson leadership will join the Department of Health – Abu Dhabi leadership, for a mainstage discussion exploring how governments, health systems and industry can work together to advance innovation, strengthen healthcare infrastructure and accelerate the future of surgery.

Surgical Intelligence Panel | Peter Schulam, M.D., Ph.D., Chief Scientific Officer, MedTech, Johnson & Johnson will moderate a panel discussion bringing together experts from across healthcare and technology to discuss the opportunities and responsibilities involved in building an open ecosystem for surgical intelligence. The conversation will explore topics including AI, data governance, research collaboration, and innovation at scale.

  1. Una nuova analisi basata su modelli conferma ulteriormente il potenziale di TECVAYLI®▼ (teclistamab) in associazione con daratumumab nel ridefinire le aspettative di sopravvivenza a lungo termine nel mieloma multiplo recidivante/refrattario trattato in prima lineaCompanies: Johnson & JohnsonJohnson & Johnson, leader mondiale nel campo del trattamento del mieloma multiplo, ha annunciato oggi nuovi dati provenienti dallo studio di Fase 3 MajesTEC-3, che dimostrano un controllo della malattia e una sopravvivenza duraturi con TECVAYLI® (teclistamab) in associazione con daratumumab nei pazienti affetti da mieloma multiplo recidivante o refrattario (RRMM) che avevano precedentemente ricevuto da 1 a 3 linee di terapia.
  2. Eine neue modellbasierte Analyse untermauert das Potenzial von TECVAYLI®▼ (teclistamab) in Kombination mit daratumumab, die Erwartungen hinsichtlich des Langzeitüberlebens bei einem rezidivierten bzw. refraktären multiplen Myelom in frühen Behandlungslinien neu zu definierenCompanies: Johnson & JohnsonJohnson & Johnson, ein weltweit führendes Unternehmen im Bereich des multiplen Myeloms, gab heute neue Daten aus der Phase III-Studie MajesTEC-3 bekannt, die eine anhaltende Krankheitskontrolle und Überlebenszeit unter TECVAYLI® (teclistamab) in Kombination mit daratumumab bei Patienten mit rezidiviertem oder refraktärem multiplem Myelom (RRMM) belegen, die zuvor 1 bis 3 Therapielinien erhalten hatten.
  3. Une nouvelle analyse modélisée renforce le potentiel de TECVAYLI®▼ (teclistamab) associé au daratumumab pour redéfinir les perspectives de survie à long terme dans le myélome multiple en rechute/réfractaire dans les premières lignes de traitementCompanies: Johnson & JohnsonBEERSE, Belgique, 28 sept. 2026 -- Johnson & Johnson, leader mondial dans le domaine du myélome multiple, a annoncé aujourd’hui de nouvelles données issues de l’étude de Phase 3 MajesTEC-3, mettant en évidence un contrôle durable de la maladie et une survie prolongée avec TECVAYLI® (teclistamab) associé au daratumumab chez des patients atteints d’un myélome multiple en rechute ou réfractaire (MMRR) ayant reçu 1 à 3 lignes de traitement antérieures.
  4. Johnson & JohnsonRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026Companies: Johnson & JohnsonLow rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival...
  5. HealthcareJohnson & JohnsonJohnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancerCompanies: Johnson & JohnsonRYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% SEOUL, South Korea, Sept. 13, 2026...
  6. FinanceJohnson & JohnsonJohnson & Johnson to Host Investor Conference Call on Third-Quarter ResultsCompanies: Johnson & JohnsonNEW BRUNSWICK, N.J., August 31, 2026--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J.